ARCHIVES

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

Zaltrap Receives Positive Opinion For European Market From CHMP

November 30, 2012

FDA Blocks Nine More INDs; Cooperative Group Chairmen, DeVita Blast “Lack of Expertise”

January 7, 1977

In Brief: Discoverer Of H. Pylori Role In Ulcers Wins Lasker Foundation Clinical Research Award

October 6, 1995

NHGRI Director Francis Collins To Step Down.

May 30, 2008

Boundary; Opponents Of CMS Policy Step Up The Fight.

November 9, 2007

NCI Resources, Services Available For Cancer Research

June 7, 1996